NIH Launches Clinical Trials Network to Test COVID-19 Vaccines, Other Prevention Strategies
The National Institute of Allergy and Infectious Diseases (NIAID) today announced it has established a new clinical trials network. The network seeks to enroll thousands of volunteers to test a variety of investigational vaccines and monoclonal antibodies intended to protect people from COVID-19.
The COVID-19 Prevention Trials Network (COVPN) was established by merging four existing NIAID-funded clinical trials networks: the HIV Vaccine Trials Network, based in Seattle; the HIV Prevention Trials Network, based in Durham, N.C.; the Infectious Diseases Clinical Research Consortium, based in Atlanta; and the AIDS Clinical Trials Group, based in Los Angeles.
The first Phase 3 clinical trial the COVPN is expected to conduct will involve testing the investigational mRNA-1273 vaccine, developed by NIAID scientists and their collaborators at the biotechnology company Moderna, Inc., based in Cambridge, Massachusetts. That study is expected to begin this summer.
Additional information about the COVPN can be found in this NIH press release.
‹ More News